Survival analysis of patients with high and low expression of the CR-high (PSMD12) and CR-low (STAC2) (see Figure 1E) genes that are co-amplified with ERBB2 showed that while the expression of CR-high genes predicted poor survival, and hence more malignant cancer phenotype, expression of the CR-low gene had a better clinical prognosis, indicating less malignant cancer phenotype (Figure 2A). Here, ERBB2 is linked to cancer.